2. Protein Tyrosine Kinase/RTK Anti-infection Autophagy
  3. Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy
  4. Imatinib

Imatinib  (Synonyms: STI571; CGP-57148B)

Cat. No.: HY-15463 Purity: 99.95%
SDS COA Handling Instructions

Molarity Calculator

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

For research use only. We do not sell to patients.

Imatinib Chemical Structure

Imatinib Chemical Structure

CAS No. : 152459-95-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 73 In-stock
Solution
10 mM * 1 mL in DMSO USD 73 In-stock
Solid
200 mg USD 66 In-stock
500 mg USD 99 In-stock
1 g USD 145 In-stock
5 g USD 257 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 91 publication(s) in Google Scholar

Other Forms of Imatinib:

Imatinib Related Antibodies

Top Publications Citing Use of Products

84 Publications Citing Use of MCE Imatinib

WB
Proliferation Assay
IHC

    Imatinib purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.  [Abstract]

    Negligible increases in caspase-3 activity or PARP-1 cleavage is observed in PC-9 GR NSCLC cells treated with DMSO, single agent PAC-1 (5 mM), or Osimertinib (Osi). In cells treated with PAC-1+Osimertinib, dramatic increases in caspase-3 activity is observed as early as 36 hr post treatment.

    Imatinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2018 Apr 24;9(31):22158-22183.  [Abstract]

    Primary tumors are dissected at the end of experiment and subjected to immunohistochemistry. Representative images of primary tumor sections stained with anti-PCNA (proliferation), anti-cleaved caspase 3 (apoptosis), and anti-CD31 (angiogenesis).

    Imatinib purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Jun 1;12(6):e0178619.  [Abstract]

    The protein expression of PDGF-A, PDGF-B, PDGF-C, and PDGF-D in hearts from mice treated with vehicle, Imatinib (IMA), ISO, IMA+ISO for one week is tested by Western blot.

    Imatinib purchased from MedChemExpress. Usage Cited in: Med Sci Monit. 2017 Aug 6;23:3808-3816.  [Abstract]

    The kinase activity of c-Kit is enhanced in an animal model of cardiac fibrosis. The lysates of heart tissues from a mice model treated with vehicle, Imatinib (IMA), ISO, or Imatinib + ISO for one week are analyzed for phosphorylation level of p-c-Kit (Tyr719) and total protein level of c-Kit. The western blotting results from one mouse in each group and the statistical analysis of the western blotting bands are shown.

    Imatinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 15;8(67):111110-111118.  [Abstract]

    In cell EC50 determination of CHMFL-KIT-031 with parental Colo320DM (KIT wt) and KIT V559D overexpressed Colo320DM cells.

    Imatinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Sep 22;59(18):8456-72.  [Abstract]

    Effect of compounds 1 (Imatinib), 2 (Sunitinib), and 35 on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.

    Imatinib purchased from MedChemExpress. Usage Cited in: J Bioenerg Biomembr. 2012 Feb;44(1):155-61.  [Abstract]

    Differences in sensitivity of PDR-mutants to 3-BP, Imatinib methanesulfonate, Daunorubicin and Rhodamine 6 G. Minimal medium (YNB) with sucrose.

    View All PDGFR Isoform Specific Products:

    View All Isoforms
    PDGFR PDGFRβ PDGFRα

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively[1][2][3][4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV[5].

    IC50 & Target

    BCR/ABL, v-Abl, PDGFR, c-kit[1][2][4]
    Cellular Effect
    Cell Line Type Value Description References
    786-0 GI50
    16 μM
    Compound: Imatinib
    Growth inhibition of human 786-0 cells measured after 48 hrs by SRB assay
    Growth inhibition of human 786-0 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    A10 IC50
    162 nM
    Compound: 1
    Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence assay
    Inhibition of PDGFR-beta driven proliferation of rat A10 cells after 68 hrs in presence of rat recombinant PDGF-BB by cell titer-glo luminescence assay
    		[PMID: 27502700]
    A2780 IC50
    4.8 x 10-5 M
    Compound: 1
    Cytotoxicity against human A2780 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human A2780 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    A2780 IC50
    8.9 μM
    Compound: Imatinib
    Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay
    		[PMID: 29684708]
    A-431 IC50
    3.1 x 10-5 M
    Compound: 1
    Cytotoxicity against human A431 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human A431 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    A498 GI50
    21.98 μM
    Compound: Imatinib
    Growth inhibition of human A498 cells measured after 48 hrs by SRB assay
    Growth inhibition of human A498 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    A549 IC50
    > 25 μM
    Compound: Imatinib
    Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against human A549 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    A549 IC50
    15.5 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human A549 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    A549 GI50
    24.49 μM
    Compound: Imatinib
    Growth inhibition of human A549 cells measured after 48 hrs by SRB assay
    Growth inhibition of human A549 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    A549 IC50
    4.56 μM
    Compound: Imatinib
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28525838]
    ACHN GI50
    25.23 μM
    Compound: Imatinib
    Growth inhibition of human ACHN cells measured after 48 hrs by SRB assay
    Growth inhibition of human ACHN cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    ASPC1 IC50
    4.4 x 10-5 M
    Compound: 1
    Cytotoxicity against human AsPC1 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human AsPC1 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    BaF3 IC50
    > 1 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    		[PMID: 26195136]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay
    		[PMID: 31250638]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of TEL fused c-KIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in mouse BAF3 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in mouse BAF3 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL T315I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL Y253F mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL Y253F mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 IC50
    > 10 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 27545040]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 29544149]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Growth inhibition of mouse BAF3 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused BLK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused DDR1 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR-fused DDR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused LCK (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused VEGFR2 (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein T315I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein Y253H mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT T670I/V559D double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT D816V mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 GI50
    > 10 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    > 10 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    > 10 μM
    Compound: 1
    Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay
    Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay
    		[PMID: 30204441]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing FIt3-ITD kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing FIt3-ITD kinase assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing TPR-MET kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing TPR-MET kinase assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-JAK1 kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-JAK1 kinase assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 IC50
    > 10 μM
    Compound: imatinib
    Cytotoxicity against mouse BA/F3 cells after 48 hrs by XTT assay
    Cytotoxicity against mouse BA/F3 cells after 48 hrs by XTT assay
    		[PMID: 23600806]
    BaF3 IC50
    > 100 nM
    Compound: Imatinib
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    BaF3 IC50
    > 100 nM
    Compound: Imatinib
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    		[PMID: 34011155]
    BaF3 IC50
    > 100 μM
    Compound: Imatinib
    Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay
    Inhibition of NPM/ALK L256T mutant kinase activity in BaF3 cells by radioenzymatic assay
    		[PMID: 16970400]
    BaF3 EC50
    > 1000 nM
    Compound: Imatinib
    Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 27010810]
    BaF3 IC50
    > 30 μM
    Compound: Imatinib
    Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    Inhibition of wild type NPM/ALK autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    		[PMID: 16970400]
    BaF3 IC50
    > 30 μM
    Compound: Imatinib
    Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    Inhibition of NPM/ALK L256T mutant autophosphorylation activity in BaF3 cells by antiphosphotyrosine immunoblotting assay
    		[PMID: 16970400]
    BaF3 IC50
    > 30 μM
    Compound: Imatinib
    Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay
    Inhibition of wild type NPM/ALK kinase activity in BaF3 cells by radioenzymatic assay
    		[PMID: 16970400]
    BaF3 GI50
    0.001 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V559G mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V559G mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    0.005 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V559A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V559A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    0.019 μM
    Compound: 1
    Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused PDGFR-beta (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 IC50
    0.027 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 GI50
    0.034 μM
    Compound: 1
    Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused PDGFR-alpha (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.039 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    0.039 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT V559D mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.039 μM
    Compound: 1
    Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 IC50
    0.092 μM
    Compound: imatinib
    Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay
    Cytotoxicity against mouse BA/F3 cells transfected with wild type Bcr-Abl after 48 hrs by XTT assay
    		[PMID: 23600806]
    BaF3 GI50
    0.1 μM
    Compound: 1
    Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 GI50
    0.102 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT L576P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.11 μM
    Compound: 1
    Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.115 μM
    Compound: 1
    Inhibition of TEL fused c-KIT L576P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT L576P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 IC50
    0.19 μM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells transfected with p210 Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells transfected with p210 Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 IC50
    0.23 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BaF3 cells expressing wild type Bcr-Abl assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    Antiproliferative activity against mouse BaF3 cells expressing wild type Bcr-Abl assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    		[PMID: 35561654]
    BaF3 IC50
    0.24 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    0.26 μM
    Compound: 1
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type C-terminal FLAG-tagged human TEL fused ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    0.267 μM
    Compound: 1
    Inhibition of TEL fused c-KIT D820E mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT D820E mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    0.27 μM
    Compound: 1
    Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of human BCR/ABL p210 fusion protein expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.29 μM
    Compound: 1
    Inhibition of wild type BCR/ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type BCR/ABL (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    0.364 μM
    Compound: 1
    Inhibition of wild type TEL fused c-KIT (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of wild type TEL fused c-KIT (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    0.37 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.38 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.4 μM
    Compound: 1
    Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 GI50
    0.406 μM
    Compound: 1
    Inhibition of TEL fused c-KIT A829P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT A829P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 IC50
    0.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    0.5 μM
    Compound: Imatinib
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    0.59 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    0.625 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein M356T mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.625 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.65 μM
    Compound: 1
    Inhibition of BCR/ABL V299L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL V299L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    0.659 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.823 μM
    Compound: 1
    Inhibition of TEL fused c-KIT D816H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT D816H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    0.85 μM
    Compound: 1
    Inhibition of BCR/ABL M351T mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL M351T mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    0.85 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein F317I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    0.855 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.95 μM
    Compound: 1
    Inhibition of BCR/ABL F317I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL F317I mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 IC50
    1 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    1.17 μM
    Compound: 1
    Inhibition of BCR/ABL Q252H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL Q252H mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    1.29 μM
    Compound: 1
    Inhibition of TEL fused c-KIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    1.29 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT N822K mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    1.29 μM
    Compound: 1
    Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 GI50
    1.57 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V654A/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V654A/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 IC50
    1.6 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    1.69 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    1.79 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein H369P mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    1.93 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    10 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay
    		[PMID: 35561654]
    BaF3 IC50
    11.1 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    110 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    12.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    12.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    12.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    129 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    13.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    1444 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    14500 nM
    Compound: Imatinib
    Growth inhibition of mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 48 hrs by MTT assay
    Growth inhibition of mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 48 hrs by MTT assay
    		[PMID: 26562217]
    BaF3 IC50
    17083 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1834 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    18520 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    1863 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    190 nM
    Compound: imatinib
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl assessed as cell viability after 48 hrs by MTT assay
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 GI50
    2.1 μM
    Compound: Imatinib
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    2.16 μM
    Compound: 1
    Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of BCR/ABL p210 fusion protein F317L mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    2.169 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    2.24 μM
    Compound: 1
    Inhibition of BCR/ABL F317L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL F317L mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 GI50
    2.3 μM
    Compound: 1
    Inhibition of TEL fused c-KIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of TEL fused c-KIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31046271]
    BaF3 GI50
    2.49 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT V654A mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    2.49 μM
    Compound: 1
    Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 IC50
    221 nM
    Compound: 1, Glivec, Gleevec
    Inhibition of human BCR-ABL1 autophosphorylation expressed in mouse BA/F3 cells by ELISA
    Inhibition of human BCR-ABL1 autophosphorylation expressed in mouse BA/F3 cells by ELISA
    		[PMID: 23611771]
    BaF3 IC50
    2377 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    2547 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    2951 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 GI50
    3 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT V559D/V654A double mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    3 μM
    Compound: 1
    Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 GI50
    3 μM
    Compound: Imatinib
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    3.3 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    3.6 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    3.75 μM
    Compound: 1
    Inhibition of BCR/ABL H369P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of BCR/ABL H369P mutant (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    BaF3 IC50
    3005 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    339 nM
    Compound: imatinib
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A337N mutant assessed as cell viability after 48 hrs by MTT assay
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A337N mutant assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 EC50
    34 nM
    Compound: Imatinib
    Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Inhibition of human wild type BCR-ABL expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 27010810]
    BaF3 IC50
    362 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    3763 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    393 nM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing NPM-abl assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells expressing NPM-abl assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 GI50
    4.1 μM
    Compound: Imatinib
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    4.686 μM
    Compound: 1
    Antiproliferative activity against mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 28541695]
    BaF3 IC50
    4.79 μM
    Compound: imatinib
    Cytotoxicity against mouse BA/F3 cells transfected with Bcr-Abl T315I mutant after 48 hrs by XTT assay
    Cytotoxicity against mouse BA/F3 cells transfected with Bcr-Abl T315I mutant after 48 hrs by XTT assay
    		[PMID: 23600806]
    BaF3 IC50
    424 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    5.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    5.6 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    55 nM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 GI50
    6.67 μM
    Compound: 1
    Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Inhibition of Tel-fused c-KIT T670I mutant (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    BaF3 GI50
    6.67 μM
    Compound: 1
    Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    BaF3 GI50
    6.7 μM
    Compound: Imatinib
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    678 nM
    Compound: 1, Glivec, Gleevec
    Inhibition of human BCR-ABL1 expressed in mouse BA/F3 cells assessed as cell growth inhibition by ATP-depletion assay
    Inhibition of human BCR-ABL1 expressed in mouse BA/F3 cells assessed as cell growth inhibition by ATP-depletion assay
    		[PMID: 23611771]
    BaF3 IC50
    7.1 μM
    Compound: Imatinib
    Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay
    Antiproliferative activity against murine BaF3 cells expressing wild type NPM/ALK by [3H]thymidine uptake assay
    		[PMID: 16970400]
    BaF3 GI50
    7.7 μM
    Compound: Imatinib
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    8615 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    88 nM
    Compound: imatinib
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH3-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    Antiproliferative activity against mouse BA/F3 cells expressing Tel-SH3-SH2-KD assessed as cell viability at 5 to 10 uM after 48 hrs by MTT assay
    		[PMID: 16415863]
    BaF3 IC50
    89 nM
    Compound: Imatinib
    Growth inhibition of mouse BA/F3 cells expressing wild-type Bcr-Abl after 48 hrs by MTT assay
    Growth inhibition of mouse BA/F3 cells expressing wild-type Bcr-Abl after 48 hrs by MTT assay
    		[PMID: 26562217]
    BaF3 IC50
    9.1 μM
    Compound: Imatinib
    Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay
    Antiproliferative activity against murine BaF3 cells expressing NPM/ALK L256T mutant by [3H]thymidine uptake assay
    		[PMID: 16970400]
    BaF3 IC50
    9.2 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    9.5 μM
    Compound: 1
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    9.7 μM
    Compound: Imatinib
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    960 nM
    Compound: 1, STI571, Glivec
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    962 nM
    Compound: imatinib
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A334l mutant assessed as cell viability after 48 hrs by MTT assay
    Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A334l mutant assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 16415863]
    BJ GI50
    > 40 μM
    Compound: Imatinib
    Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human BJ cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 31514019]
    BT-549 GI50
    16.11 μM
    Compound: Imatinib
    Growth inhibition of human BT-549 cells measured after 48 hrs by SRB assay
    Growth inhibition of human BT-549 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    BV-173 GI50
    0.1 μM
    Compound: Imatinib
    Antiproliferative activity against human BV173 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    Antiproliferative activity against human BV173 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    		[PMID: 27011159]
    BV-173 IC50
    20 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human BV173 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 24681986]
    CAKI-1 GI50
    33.96 μM
    Compound: Imatinib
    Growth inhibition of human CAKI-1 cells measured after 48 hrs by SRB assay
    Growth inhibition of human CAKI-1 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    CAL-27 IC50
    2.2 x 10-5 M
    Compound: 1
    Cytotoxicity against human CAL27 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human CAL27 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    CCRF-CEM GI50
    16.98 μM
    Compound: Imatinib
    Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 32961435]
    CCRF-CEM GI50
    16.98 μM
    Compound: Imatinib
    Growth inhibition of human CCRF-CEM cells measured after 48 hrs by SRB assay
    Growth inhibition of human CCRF-CEM cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    CCRF-CEM GI50
    35.809 μM
    Compound: Imatinib
    Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human CEM cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 31514019]
    CCRF-CEM IC50
    36 μM
    Compound: 1
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human CCRF-CEM cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    CCRF-CEM IC50
    45 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human CCRF-CEM cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 24681986]
    CCRF-CEM/VCR-1000 IC50
    3.7 x 10-5 M
    Compound: 1
    Cytotoxicity against vincristine-resistant human CCRF-CEM/VCR1000 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against vincristine-resistant human CCRF-CEM/VCR1000 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in CHO cells after 72 hrs by CCK8 assay
    Antiproliferative activity in CHO cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against CHO cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against CHO cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 28541695]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against CHO cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    CHO GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    COLO 205 GI50
    17.62 μM
    Compound: Imatinib
    Growth inhibition of human COLO 205 cells measured after 48 hrs by SRB assay
    Growth inhibition of human COLO 205 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    DU-145 GI50
    18.79 μM
    Compound: Imatinib
    Growth inhibition of human DU-145 cells measured after 48 hrs by SRB assay
    Growth inhibition of human DU-145 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    EKVX GI50
    26.18 μM
    Compound: Imatinib
    Growth inhibition of human EKVX cells measured after 48 hrs by SRB assay
    Growth inhibition of human EKVX cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    EM-2 GI50
    0.26 μM
    Compound: Imatinib
    Antiproliferative activity against human EM2 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    Antiproliferative activity against human EM2 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    		[PMID: 27011159]
    EOL1 GI50
    < 0.0005 μM
    Compound: Imatinib
    Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against FIP1L1-PDGFRA positive human EOL-1 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 31514019]
    EOL1 GI50
    < 0.001 μM
    Compound: 1
    Antiproliferative activity against human EOL-1 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human EOL-1 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 29544149]
    EOL1 IC50
    0.0002 μM
    Compound: 1
    Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human EOL-1 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    GIST430 GI50
    1100 nM
    Compound: 1
    Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    		[PMID: 28991465]
    GIST430 GI50
    625 nM
    Compound: 1
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining
    		[PMID: 31721578]
    GIST430 GI50
    929 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay
    		[PMID: 30968693]
    GIST430 GI50
    929 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass
    Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass
    		[PMID: 30968693]
    GIST48 IC50
    18.7 μM
    Compound: imatinib
    Cytotoxicity against human GIST48 cells assessed as effect on cell viability after 3 to 6 days by luciferase based luminescence assay
    Cytotoxicity against human GIST48 cells assessed as effect on cell viability after 3 to 6 days by luciferase based luminescence assay
    		[PMID: 19469547]
    GIST48 GI50
    625 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay
    		[PMID: 30968693]
    GIST48 GI50
    625 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay
    		[PMID: 30968693]
    GIST48 GI50
    929 nM
    Compound: 1
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay
    Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay
    		[PMID: 31721578]
    GIST882 GI50
    0.014 μM
    Compound: 1
    Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human GIST882 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    GIST882 GI50
    0.014 μM
    Compound: 1
    Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    GIST882 GI50
    0.02 μM
    Compound: 1
    Antiproliferative activity against human GIST882 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human GIST882 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 28541695]
    GIST882 GI50
    0.058 μM
    Compound: 1
    Antiproliferative activity against human GIST882 cells harboring c-KIT K642E mutant incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT K642E mutant incubated for 72 hrs by CCK8 assay
    		[PMID: 31046271]
    GIST882 IC50
    1.7 μM
    Compound: imatinib
    Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
    Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
    		[PMID: 19469547]
    GIST882 GI50
    195 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay
    		[PMID: 30968693]
    GIST882 GI50
    195 nM
    Compound: 1
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay
    		[PMID: 31721578]
    GIST882 GI50
    195 nM
    Compound: Imatinib
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay
    Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay
    		[PMID: 30968693]
    GISTT1 GI50
    > 10 μM
    Compound: 1
    Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31250638]
    GISTT1 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I double mutant incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion/T670I double mutant incubated for 72 hrs by CCK8 assay
    		[PMID: 31046271]
    GISTT1 GI50
    0.003 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 28541695]
    GISTT1 GI50
    0.008 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human GISTT1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    GISTT1 GI50
    0.008 μM
    Compound: 1
    Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    GISTT1 GI50
    0.015 μM
    Compound: 1
    Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay
    		[PMID: 31250638]
    GISTT1 GI50
    0.026 μM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human GISTT1 cells harboring c-KIT 560 to 578 deletion mutant incubated for 72 hrs by CCK8 assay
    		[PMID: 31046271]
    GISTT1 GI50
    40 nM
    Compound: 1
    Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay
    		[PMID: 28991465]
    GISTT1 GI50
    40 nM
    Compound: 1
    Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
    Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
    		[PMID: 31721578]
    HCC 2998 GI50
    21.23 μM
    Compound: Imatinib
    Growth inhibition of human HCC 2998 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HCC 2998 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HCC827 GI50
    > 40 μM
    Compound: Imatinib
    Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human HCC827 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 31514019]
    HCT-116 IC50
    1 x 10-5 M
    Compound: 1
    Cytotoxicity against human HCT116 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human HCT116 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    HCT-116 GI50
    12.59 μM
    Compound: Imatinib
    Growth inhibition of human HCT-116 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HCT-116 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HCT-116 IC50
    19.66 μM
    Compound: Imatinib
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29684708]
    HCT-116 IC50
    34.3 μM
    Compound: Imatinib
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 33129590]
    HCT-116 IC50
    44.55 μM
    Compound: Imatinib
    Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against p53+/+ human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    HCT-116 IC50
    51.21 μM
    Compound: Imatinib
    Antiproliferative activity against p53-/- human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against p53-/- human HCT116 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    HCT-15 GI50
    19.95 μM
    Compound: Imatinib
    Growth inhibition of human HCT-15 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HCT-15 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HCT-15 IC50
    2.5 x 10-5 M
    Compound: 1
    Cytotoxicity against human HCT15 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human HCT15 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    HEC-1-A IC50
    1.9 x 10-5 M
    Compound: 1
    Cytotoxicity against human Hec1A cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human Hec1A cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    HEK293 IC50
    > 10 μM
    Compound: STI571
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay
    		[PMID: 35944901]
    HEK293 IC50
    0.05 μM
    Compound: imatinib
    Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis
    Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis
    		[PMID: 23241029]
    HEK293 IC50
    0.35 μM
    Compound: imatinib
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay
    		[PMID: 23241029]
    HEK293 IC50
    0.35 μM
    Compound: imatinib
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    		[PMID: 23241029]
    HEK293 IC50
    107 μM
    Compound: imatinib
    Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    		[PMID: 23241029]
    HEK293 IC50
    141 nM
    Compound: gleevec, ST1571
    Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA
    		[PMID: 20817538]
    HEK293 IC50
    2.9 μM
    Compound: imatinib
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
    		[PMID: 23241029]
    HEK293 IC50
    25.5 μM
    Compound: imatinib
    Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    		[PMID: 23241029]
    HEK293 IC50
    291 nM
    Compound: gleevec, ST1571
    Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA
    		[PMID: 20817538]
    HEK293 IC50
    4.2 μM
    Compound: imatinib
    Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay
    		[PMID: 23241029]
    HEK293 IC50
    43 nM
    Compound: gleevec, ST1571
    Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA
    		[PMID: 20817538]
    HEK-293T CC50
    27.54 μM
    Compound: Imatinib
    Cytotoxicity against human 293T cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Cytotoxicity against human 293T cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 28029512]
    HEL GI50
    5.3 μM
    Compound: Imatinib
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    HeLa IC50
    18.65 μM
    Compound: 1
    Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human HeLa cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    HeLa CC50
    38.8 μg/mL
    Compound: imatinib
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
    		[PMID: 20153202]
    HepG2 IC50
    > 25 μM
    Compound: Imatinib
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 26707846]
    HepG2 IC50
    10 μM
    Compound: Imatinib
    Antiproliferative activity against human HepG2 cells after 24 to 96 hrs by MTS assay
    Antiproliferative activity against human HepG2 cells after 24 to 96 hrs by MTS assay
    		[PMID: 23932071]
    HGC-27 IC50
    2.4 μM
    Compound: Imatinib
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    		[PMID: 29724653]
    HGC-27 IC50
    2.4 μM
    Compound: imatinib
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
    		[PMID: 19469547]
    HGC-27 IC50
    3.8 μM
    Compound: Imatinib
    Cytotoxicity against HGC27 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against HGC27 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 24900584]
    HL-60 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in human HL60 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human HL60 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    HL-60 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human HL60 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    HL-60 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    HL-60 IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against human HL60 Bcr-abl negative cells assessed as cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HL60 Bcr-abl negative cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 16415863]
    HL-60 IC50
    0.03 μM
    Compound: Imatinib
    Antiproliferative activity against human HL60 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    		[PMID: 26850004]
    HL-60 IC50
    28.54 μM
    Compound: Imatinib
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 36242991]
    HL-60 IC50
    55 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human HL60 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 24681986]
    HL-60(TB) GI50
    13.49 μM
    Compound: Imatinib
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 32961435]
    HL-60(TB) GI50
    13.49 μM
    Compound: Imatinib
    Growth inhibition of human HL-60(TB) cells measured after 48 hrs by SRB assay
    Growth inhibition of human HL-60(TB) cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HOP-62 GI50
    21.53 μM
    Compound: Imatinib
    Growth inhibition of human HOP-62 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HOP-62 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HOP-92 GI50
    13.34 μM
    Compound: Imatinib
    Growth inhibition of human HOP-92 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HOP-92 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HOS-TE85 IC50
    20.5 μM
    Compound: Imatinib
    Antiproliferative activity against human MNNG/HOS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MNNG/HOS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35239349]
    Hs-578T GI50
    14.59 μM
    Compound: Imatinib
    Growth inhibition of human Hs-578T cells measured after 48 hrs by SRB assay
    Growth inhibition of human Hs-578T cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HT-29 IC50
    0.06 μM
    Compound: Imatinib
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    		[PMID: 29724653]
    HT-29 IC50
    0.06 μM
    Compound: imatinib
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
    		[PMID: 19469547]
    HT-29 GI50
    3.97 μM
    Compound: Imatinib
    Growth inhibition of human HT-29 cells measured after 48 hrs by SRB assay
    Growth inhibition of human HT-29 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    HUVEC GI50
    10.9 μg/mL
    Compound: imatinib
    Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay
    Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay
    		[PMID: 20153202]
    IGROV-1 GI50
    21.18 μM
    Compound: Imatinib
    Growth inhibition of human IGROV-1 cells measured after 48 hrs by SRB assay
    Growth inhibition of human IGROV-1 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    Jurkat IC50
    > 10 μM
    Compound: imatinib
    Antiproliferative activity against human Jurkat Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human Jurkat Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    Jurkat IC50
    > 1000 nM
    Compound: Imatinib
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    K562 GI50
    > 10 μM
    Compound: STI571
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    		[PMID: 35944901]
    K562 GI50
    0.02 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 32961435]
    K562 GI50
    0.02 μM
    Compound: Imatinib
    Growth inhibition of human K562 cells measured after 48 hrs by SRB assay
    Growth inhibition of human K562 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    K562 IC50
    0.049 μM
    Compound: 1
    Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human K562 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    K562 GI50
    0.1 ng/mL
    Compound: imatinib
    Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay
    Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay
    		[PMID: 20153202]
    K562 IC50
    0.1 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    		[PMID: 22632935]
    K562 IC50
    0.109 μM
    Compound: imatinib
    Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    K562 GI50
    0.12 μM
    Compound: 1
    Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    K562 IC50
    0.135 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 36242991]
    K562 GI50
    0.14 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    K562 IC50
    0.14 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by real time live-cell imaging technique
    		[PMID: 31097376]
    K562 GI50
    0.147 μM
    Compound: 1
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 28541695]
    K562 IC50
    0.15 nM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 30605831]
    K562 IC50
    0.18 μM
    Compound: gleevec
    Cytotoxicity against K562 cells by MTT assay
    Cytotoxicity against K562 cells by MTT assay
    		[PMID: 17572088]
    K562 GI50
    0.2 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    Antiproliferative activity against human K562 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    		[PMID: 27011159]
    K562 IC50
    0.22 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by trypan blue dye exclusion assay
    Antiproliferative activity against human K562 cells after 48 hrs by trypan blue dye exclusion assay
    		[PMID: 26629859]
    K562 GI50
    0.25 μM
    Compound: 1
    Antiproliferative activity in human K562 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human K562 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    K562 GI50
    0.267 μM
    Compound: 1
    Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human K562 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    K562 IC50
    0.28 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    		[PMID: 26195136]
    K562 IC50
    0.38 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    		[PMID: 26850004]
    K562 GI50
    0.39 μM
    Compound: 1, Gleevec
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells after 72 hrs by MTS assay
    		[PMID: 22932313]
    K562 IC50
    0.4 μM
    Compound: STI-571 imatinib
    Inhibitory activity against human K562 cells growth using MTT assay
    Inhibitory activity against human K562 cells growth using MTT assay
    		[PMID: 14552760]
    K562 IC50
    0.47 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 25778766]
    K562 IC50
    0.47 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 23735826]
    K562 IC50
    0.5 μM
    Compound: imatinib
    Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay
    Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay
    		[PMID: 25757603]
    K562 IC50
    0.5 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 23932071]
    K562 IC50
    0.5 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay
    Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay
    		[PMID: 23981532]
    K562 IC50
    0.51 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26814890]
    K562 IC50
    0.53 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28525838]
    K562 IC50
    0.53 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 26707846]
    K562 GI50
    0.563 μM
    Compound: STI571
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    		[PMID: 35944901]
    K562 IC50
    0.58 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 21295380]
    K562 IC50
    0.61 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells by MTT assay
    Antiproliferative activity against human K562 cells by MTT assay
    		[PMID: 33132117]
    K562 GI50
    0.73 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence analysis
    		[PMID: 31514019]
    K562 IC50
    0.73 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
    		[PMID: 26741853]
    K562 IC50
    0.75 μM
    Compound: Imatinib
    Inhibition of BCR/ABL p210 autophosphorylation in human K562 cells after 2 hrs by Western blot analysis
    Inhibition of BCR/ABL p210 autophosphorylation in human K562 cells after 2 hrs by Western blot analysis
    		[PMID: 20188579]
    K562 GI50
    0.8 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32961435]
    K562 IC50
    1 μM
    Compound: IM
    Cytotoxicity against imatinib-sensitive human K562 cells assessed as decrease in cell viability after 24 hrs by XTT assay
    Cytotoxicity against imatinib-sensitive human K562 cells assessed as decrease in cell viability after 24 hrs by XTT assay
    		[PMID: 30261468]
    K562 IC50
    1.1 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35561654]
    K562 IC50
    1.1 μM
    Compound: Imatinib
    Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    		[PMID: 29655981]
    K562 IC50
    1.16 μM
    Compound: STI571
    Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 26451772]
    K562 IC50
    1.16 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 26231079]
    K562 IC50
    13 μM
    Compound: Imatinib
    In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    In vitro antiproliferative activity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    		[PMID: 24681986]
    K562 IC50
    15.7 μM
    Compound: Imatinib
    Antiproliferative activity against imatinib-resistant human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against imatinib-resistant human K562 cells after 48 hrs by MTT assay
    		[PMID: 26231079]
    K562 IC50
    250 nM
    Compound: Imatinib
    Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    		[PMID: 28280261]
    K562 IC50
    272 nM
    Compound: Imatinib
    Inhibition of kinobead binding to ARG in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to ARG in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    		[PMID: 28280261]
    K562 IC50
    3.43 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 29684708]
    K562 IC50
    310 nM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as decrease in cell proliferation after 72 hrs by XTT assay
    Cytotoxicity against human K562 cells assessed as decrease in cell proliferation after 72 hrs by XTT assay
    		[PMID: 27214512]
    K562 IC50
    384.4 nM
    Compound: STI571, Gleevec
    Cytotoxicity against human BCR-ABL positive K562 cells after 48 to 72 hrs by MTT assay
    Cytotoxicity against human BCR-ABL positive K562 cells after 48 to 72 hrs by MTT assay
    		[PMID: 22789429]
    K562 IC50
    4.12 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 26298495]
    K562 IC50
    4.12 μM
    Compound: Imatinib
    Antiproliferative activity against Bcr/Abl positive human K562 cells after 48 hrs by MTT method
    Antiproliferative activity against Bcr/Abl positive human K562 cells after 48 hrs by MTT method
    		[PMID: 25464886]
    K562 IC50
    4.26 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 34547714]
    K562 IC50
    4.26 μM
    Compound: STI-571
    Antiproliferative activity against human BCR/ABL positive K562 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human BCR/ABL positive K562 cells assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31185413]
    K562 IC50
    4.63 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells by MTS assay
    Antiproliferative activity against human K562 cells by MTS assay
    		[PMID: 34015503]
    K562 IC50
    43 nM
    Compound: Imatinib
    Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    		[PMID: 28280261]
    K562 IC50
    5.4 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 21576023]
    K562 IC50
    7.38 μM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 28029512]
    K562 IC50
    76.2 nM
    Compound: Imatinib
    Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay
    Antiproliferative activity against human K562 cells incubated for 3 days by CCK8 assay
    		[PMID: 32657579]
    K562 IC50
    82.9 nM
    Compound: Imatinib
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    K562 IC50
    87.32 μM
    Compound: Imatinib
    Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
    		[PMID: 33938746]
    K562 IC50
    90 nM
    Compound: Imatinib
    Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    		[PMID: 28280261]
    K562/A02 IC50
    0.98 μM
    Compound: Imatinib
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    		[PMID: 33132117]
    K562/A02 IC50
    75.69 μM
    Compound: Imatinib
    Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay
    		[PMID: 33938746]
    K562/Adr IC50
    13.47 μM
    Compound: Imatinib
    Antiproliferative activity against human Adriamycin-resistant K562/Adr cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Adriamycin-resistant K562/Adr cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35561654]
    K-562R IC50
    > 50 μM
    Compound: Imatinib
    Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay
    		[PMID: 29655981]
    K-562R IC50
    90 μM
    Compound: STI-571
    Antiproliferative activity against human K562R cells expressing BCR/ABL T315I mutant assessed as growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human K562R cells expressing BCR/ABL T315I mutant assessed as growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31185413]
    K-562R IC50
    93.01 μM
    Compound: Imatinib
    Antiproliferative activity against human K-562R cells expressing Bcr-Abl T315I mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human K-562R cells expressing Bcr-Abl T315I mutant assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35561654]
    K-562R IC50
    98.82 μM
    Compound: IM
    Cytotoxicity against human K562R cells assessed as decrease in cell viability after 24 hrs by XTT assay
    Cytotoxicity against human K562R cells assessed as decrease in cell viability after 24 hrs by XTT assay
    		[PMID: 30261468]
    KBM5 IC50
    0.28 μM
    Compound: STI-571
    Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTT assay
    Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTT assay
    		[PMID: 20149665]
    KBM5 IC50
    5.4 μM
    Compound: STI-571
    Cytotoxicity against human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTT assay
    Cytotoxicity against human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTT assay
    		[PMID: 20149665]
    KCL-22 GI50
    0.43 μM
    Compound: Imatinib
    Antiproliferative activity against human KCL22 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    Antiproliferative activity against human KCL22 cells after 48 hrs by Cell-Titer-Glo luminescent cell viability assay
    		[PMID: 27011159]
    KG-1a IC50
    16.7 μM
    Compound: Imatinib
    Antiproliferative activity against human KG1a cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    Antiproliferative activity against human KG1a cells assessed as inhibition of cell survival after 72 hrs by MTT assay
    		[PMID: 26850004]
    KM12 GI50
    18.84 μM
    Compound: Imatinib
    Growth inhibition of human KM12 cells measured after 48 hrs by SRB assay
    Growth inhibition of human KM12 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    KU812 cell line GI50
    0.11 μM
    Compound: 1
    Antiproliferative activity against human KU812 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human KU812 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 28541695]
    KU812 cell line GI50
    0.16 μM
    Compound: 1
    Antiproliferative activity against BCR-ABL dependent human KU812 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against BCR-ABL dependent human KU812 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    KU812 cell line GI50
    0.16 μM
    Compound: Imatinib
    Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    KU812 cell line GI50
    0.163 μM
    Compound: 1
    Antiproliferative activity against human KU812 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human KU812 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    KU812 cell line GI50
    0.31 μM
    Compound: 1
    Antiproliferative activity in human KU812 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human KU812 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    KU812 cell line IC50
    51.3 nM
    Compound: Imatinib
    Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    L02 IC50
    > 100 μM
    Compound: Imatinib
    Antiproliferative activity against human L02 cells by MTS assay
    Antiproliferative activity against human L02 cells by MTS assay
    		[PMID: 34015503]
    L132 GI50
    > 10 μM
    Compound: Imatinib
    Antiproliferative activity against human L132 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against human L132 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 32961435]
    Leukemia cell IC50
    0.1 μM
    Compound: 4
    Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay
    Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay
    		[PMID: 22221201]
    Leukemia cell IC50
    0.5 μM
    Compound: 4
    Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay
    Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay
    		[PMID: 22221201]
    LOX IMVI GI50
    18.11 μM
    Compound: Imatinib
    Growth inhibition of human LOX IMVI cells measured after 48 hrs by SRB assay
    Growth inhibition of human LOX IMVI cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    M14 GI50
    19.28 μM
    Compound: Imatinib
    Growth inhibition of human M14 cells measured after 48 hrs by SRB assay
    Growth inhibition of human M14 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    Malme-3M GI50
    16.33 μM
    Compound: Imatinib
    Growth inhibition of human Malme-3M cells measured after 48 hrs by SRB assay
    Growth inhibition of human Malme-3M cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    MCF-10A IC50
    > 100 μM
    Compound: Imatinib
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30798049]
    MCF7 IC50
    > 10 μM
    Compound: imatinib
    Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay
    Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay
    		[PMID: 25757603]
    MCF7 IC50
    > 10 μM
    Compound: Imatinib
    Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
    Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method
    		[PMID: 26741853]
    MCF7 IC50
    > 10 μM
    Compound: Imatinib
    Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay
    Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay
    		[PMID: 23981532]
    MCF7 IC50
    > 25 μM
    Compound: Imatinib
    Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    MCF7 IC50
    11.3 μM
    Compound: Imatinib
    Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
    		[PMID: 29724653]
    MCF7 IC50
    11.5 μM
    Compound: imatinib
    Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
    		[PMID: 19469547]
    MCF7 GI50
    18.24 μM
    Compound: Imatinib
    Growth inhibition of human MCF7 cells measured after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    MCF7 IC50
    3 x 10-5 M
    Compound: 1
    Cytotoxicity against human MCF7 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human MCF7 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    MCF7 IC50
    4.07 μM
    Compound: Imatinib
    Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining
    Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining
    		[PMID: 19932960]
    MCF7 IC50
    6.33 μM
    Compound: Imatinib
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30798049]
    MCF7 IC50
    7.12 μM
    Compound: Imatinib
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 29684708]
    MDA-MB-231 GI50
    18.66 μM
    Compound: Imatinib
    Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    MDA-MB-231 IC50
    3.7 x 10-5 M
    Compound: 1
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    MDA-MB-435 GI50
    17.91 μM
    Compound: Imatinib
    Growth inhibition of human MDA-MB-435 cells measured after 48 hrs by SRB assay
    Growth inhibition of human MDA-MB-435 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    MDA-MB-453 IC50
    12.84 μM
    Compound: Imatinib
    Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 30798049]
    MDA-MB-468 IC50
    1.7 x 10-5 M
    Compound: 1
    Cytotoxicity against human MDA-MB-468 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human MDA-MB-468 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    MDCK IC50
    3.38 μM
    Compound: Imatinib
    Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay
    Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay
    		[PMID: 19932960]
    MDCK-II IC50
    > 100 μM
    Compound: Imatinib
    Cytotoxicity against BCRP-overexpressing MDCK-II cells incubated for 48 hrs by MTT assay
    Cytotoxicity against BCRP-overexpressing MDCK-II cells incubated for 48 hrs by MTT assay
    		[PMID: 33938746]
    MDCK-II IC50
    0.04 μM
    Compound: imatinib
    Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis
    Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis
    		[PMID: 23241029]
    MDCK-II IC50
    65.82 μM
    Compound: Imatinib
    Cytotoxicity against MDCK-II cells incubated for 48 hrs by MTT assay
    Cytotoxicity against MDCK-II cells incubated for 48 hrs by MTT assay
    		[PMID: 33938746]
    MEC1 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in human MEC1 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human MEC1 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    MEG-01 GI50
    0.045 μM
    Compound: 1
    Antiproliferative activity against human MEG01 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    Antiproliferative activity against human MEG01 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay
    		[PMID: 28541695]
    MEG-01 GI50
    0.074 μM
    Compound: 1
    Antiproliferative activity against human MEG01 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human MEG01 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    MEG-01 GI50
    0.074 μM
    Compound: 1
    Antiproliferative activity against human BCR-ABL dependent MEG01 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against human BCR-ABL dependent MEG01 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    MEG-01 GI50
    0.24 μM
    Compound: Imatinib
    Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    MEG-01 GI50
    0.28 μM
    Compound: 1
    Antiproliferative activity in human MEG01 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human MEG01 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    MG-63 IC50
    31.69 μM
    Compound: Imatinib
    Antiproliferative activity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MG-63 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35239349]
    MOLM-13 GI50
    > 1000 nM
    Compound: 1
    Antiproliferative activity against human MOLM13 harboring FLT3-ITD mutant assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
    Antiproliferative activity against human MOLM13 harboring FLT3-ITD mutant assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
    		[PMID: 31721578]
    MOLM-14 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human MOLM14 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human MOLM14 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    MOLM-14 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against FLT3-ITD dependent human MOLM14 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against FLT3-ITD dependent human MOLM14 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    MOLM-14 GI50
    > 10 μM
    Compound: Imatinib
    Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    MOLT-4 GI50
    5.13 μM
    Compound: Imatinib
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 32961435]
    MOLT-4 GI50
    5.13 μM
    Compound: Imatinib
    Growth inhibition of human MOLT-4 cells measured after 48 hrs by SRB assay
    Growth inhibition of human MOLT-4 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    MV4-11 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human MV4-11 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human MV4-11 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    MV4-11 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against FLT3-ITD dependent human MV4-11 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against FLT3-ITD dependent human MV4-11 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    MV4-11 GI50
    > 10 μM
    Compound: Imatinib
    Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    NCI/ADR-RES GI50
    22.96 μM
    Compound: Imatinib
    Growth inhibition of human NCI/ADR-RES cells measured after 48 hrs by SRB assay
    Growth inhibition of human NCI/ADR-RES cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    NCI-H1703 GI50
    0.23 μM
    Compound: 1
    Antiproliferative activity against human NCI-H1703 cells after 72 hrs in presence of PDGF-AA by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human NCI-H1703 cells after 72 hrs in presence of PDGF-AA by CellTiter-Glo or CCK-8 assay
    		[PMID: 29544149]
    NCI-H1703 GI50
    2.1 μM
    Compound: 1
    Antiproliferative activity against human NCI-H1703 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human NCI-H1703 cells after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 29544149]
    NCI-H226 GI50
    18.11 μM
    Compound: Imatinib
    Growth inhibition of human NCI-H226 cells measured after 48 hrs by SRB assay
    Growth inhibition of human NCI-H226 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    NCI-H23 GI50
    14.96 μM
    Compound: Imatinib
    Growth inhibition of human NCI-H23 cells measured after 48 hrs by SRB assay
    Growth inhibition of human NCI-H23 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    NCI-H322M GI50
    22.8 μM
    Compound: Imatinib
    Growth inhibition of human NCI-H322M cells measured after 48 hrs by SRB assay
    Growth inhibition of human NCI-H322M cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    NCI-H460 GI50
    16.18 μM
    Compound: Imatinib
    Growth inhibition of human NCI-H460 cells measured after 48 hrs by SRB assay
    Growth inhibition of human NCI-H460 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    NCI-H460 IC50
    2.4 x 10-5 M
    Compound: 1
    Cytotoxicity against human H460 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human H460 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    NCI-H522 GI50
    16.41 μM
    Compound: Imatinib
    Growth inhibition of human NCI-H522 cells measured after 48 hrs by SRB assay
    Growth inhibition of human NCI-H522 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    NCI-H69 IC50
    3.2 x 10-5 M
    Compound: 1
    Cytotoxicity against human H69 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human H69 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    NHDF IC50
    > 25 μM
    Compound: Imatinib
    Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay
    Antiproliferative activity against human NHDF cells after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 30562697]
    OCI-AML2 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in human OCI-AML2 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human OCI-AML2 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    OVCAR-3 GI50
    34.2 μM
    Compound: Imatinib
    Growth inhibition of human OVCAR-3 cells measured after 48 hrs by SRB assay
    Growth inhibition of human OVCAR-3 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    OVCAR-4 GI50
    20.04 μM
    Compound: Imatinib
    Growth inhibition of human OVCAR-4 cells measured after 48 hrs by SRB assay
    Growth inhibition of human OVCAR-4 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    OVCAR-5 GI50
    0.58 μM
    Compound: Imatinib
    Growth inhibition of human OVCAR-5 cells measured after 48 hrs by SRB assay
    Growth inhibition of human OVCAR-5 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    OVCAR-8 GI50
    27.67 μM
    Compound: Imatinib
    Growth inhibition of human OVCAR-8 cells measured after 48 hrs by SRB assay
    Growth inhibition of human OVCAR-8 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    PC-3 IC50
    2.4 x 10-5 M
    Compound: 1
    Cytotoxicity against human PC3 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human PC3 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    PC-3 GI50
    21.38 μM
    Compound: Imatinib
    Growth inhibition of human PC-3 cells measured after 48 hrs by SRB assay
    Growth inhibition of human PC-3 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    Rec1 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human Rec1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human Rec1 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    Rec1 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human Rec1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against human Rec1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    RPMI-8226 GI50
    6.05 μM
    Compound: Imatinib
    Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 32961435]
    RPMI-8226 GI50
    6.05 μM
    Compound: Imatinib
    Growth inhibition of human RPMI-8226 cells measured after 48 hrs by SRB assay
    Growth inhibition of human RPMI-8226 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    RXF 393 GI50
    15.07 μM
    Compound: Imatinib
    Growth inhibition of human RXF 393 cells measured after 48 hrs by SRB assay
    Growth inhibition of human RXF 393 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SAOS-2 IC50
    15.01 μM
    Compound: Imatinib
    Antiproliferative activity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SAOS-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35239349]
    SAOS-2 IC50
    2.6 x 10-5 M
    Compound: 1
    Cytotoxicity against human Saos2 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human Saos2 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    SF-268 GI50
    26.3 μM
    Compound: Imatinib
    Growth inhibition of human SF-268 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SF-268 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SF-295 GI50
    19.77 μM
    Compound: Imatinib
    Growth inhibition of human SF-295 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SF-295 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SF-539 GI50
    10.57 μM
    Compound: Imatinib
    Growth inhibition of human SF-539 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SF-539 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    Sf9 IC50
    > 10 μM
    Compound: 1
    Inhibition of active wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay
    Inhibition of active wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay
    		[PMID: 30317026]
    Sf9 IC50
    > 10 μM
    Compound: 1
    Inhibition of inactive wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8
    Inhibition of inactive wild type His-tagged ABL T315I mutant (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8
    		[PMID: 30317026]
    Sf9 IC50
    > 100 μM
    Compound: Imatinib
    Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP
    Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP
    		[PMID: 26741853]
    Sf9 IC50
    > 100 μM
    Compound: Imatinib
    Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP
    Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP
    		[PMID: 24681986]
    Sf9 IC50
    0.043 μM
    Compound: 1
    Inhibition of inactive wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8 hrs by ADP-G
    Inhibition of inactive wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in autophosphorylation preincubated for 60 mins followed by ATP addition measured after 8 hrs by ADP-G
    		[PMID: 30317026]
    Sf9 IC50
    0.3 μM
    Compound: Imatinib
    Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP
    Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP
    		[PMID: 24681986]
    Sf9 IC50
    1.5 μM
    Compound: 1
    Inhibition of active wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay
    Inhibition of active wild type His-tagged ABL (229 to 500 residues) (unknown origin) expressed in baculovirus infected sf9 cells using ABLtide as substrate after 1 hr by ADP-Glo assay
    		[PMID: 30317026]
    Sf9 IC50
    131 nM
    Compound: 1
    Inhibition of wild type recombinant GST-tagged FLT3 (Y567 to S993 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using Her2 peptide as substrate measured after 4 hrs in presence of ATP by Kinase-Glo Plus reagent-based lumine
    Inhibition of wild type recombinant GST-tagged FLT3 (Y567 to S993 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using Her2 peptide as substrate measured after 4 hrs in presence of ATP by Kinase-Glo Plus reagent-based lumine
    		[PMID: 31721578]
    Sf9 IC50
    223 nM
    Compound: 1
    Inhibition of C-terminal His-tagged human ABL1 expressed in baculovirus infected SF9 cells using Tyr 02 peptide as substrate measured after 1 hr by FRET based Z'Lyte assay
    Inhibition of C-terminal His-tagged human ABL1 expressed in baculovirus infected SF9 cells using Tyr 02 peptide as substrate measured after 1 hr by FRET based Z'Lyte assay
    		[PMID: 27966954]
    Sf9 IC50
    319 nM
    Compound: 1
    Inhibition of His-tagged cKIT (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay
    Inhibition of His-tagged cKIT (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay
    		[PMID: 27545040]
    Sf9 IC50
    5210 nM
    Compound: Imatinib
    Inhibition of ATP-activated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 3
    Inhibition of ATP-activated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 3
    		[PMID: 30968693]
    Sf9 IC50
    53 nM
    Compound: 1
    Inhibition of recombinant N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) (unknown origin) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr) 4:1 as substrate measured after 150 mins in presence of
    Inhibition of recombinant N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) (unknown origin) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr) 4:1 as substrate measured after 150 mins in presence of
    		[PMID: 31721578]
    Sf9 IC50
    769 nM
    Compound: Imatinib
    Inhibition of unactivated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 30
    Inhibition of unactivated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 30
    		[PMID: 30968693]
    Sf9 IC50
    9818 nM
    Compound: 1
    Inhibition of His-tagged cKIT T670I mutant (544 to 935 residues) (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay
    Inhibition of His-tagged cKIT T670I mutant (544 to 935 residues) (unknown origin) expressed in Sf9 cells using Poly(4:1 Glu, Tyr) peptide as substrate after 1 hr by ADP-glo kinase assay
    		[PMID: 27545040]
    SK-BR-3 IC50
    3.9 x 10-5 M
    Compound: 1
    Cytotoxicity against human SKBR3 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    SK-MEL-2 GI50
    25 μM
    Compound: Imatinib
    Growth inhibition of human SK-MEL-2 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SK-MEL-2 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SK-MEL-28 GI50
    14.62 μM
    Compound: Imatinib
    Growth inhibition of human SK-MEL-28 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SK-MEL-28 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SK-MEL-5 GI50
    12.13 μM
    Compound: Imatinib
    Growth inhibition of human SK-MEL-5 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SK-MEL-5 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SK-OV-3 GI50
    28.91 μM
    Compound: Imatinib
    Growth inhibition of human SK-OV-3 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SK-OV-3 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SK-OV-3 IC50
    5.3 x 10-5 M
    Compound: 1
    Cytotoxicity against human SKOV3 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    SN12C GI50
    33.19 μM
    Compound: Imatinib
    Growth inhibition of human SN12C cells measured after 48 hrs by SRB assay
    Growth inhibition of human SN12C cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SNB-19 GI50
    38.55 μM
    Compound: Imatinib
    Growth inhibition of human SNB-19 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SNB-19 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SNB-75 GI50
    20.28 μM
    Compound: Imatinib
    Growth inhibition of human SNB-75 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SNB-75 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SR GI50
    7.14 μM
    Compound: Imatinib
    Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Antiproliferative activity against human SR cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 32961435]
    SR GI50
    7.14 μM
    Compound: Imatinib
    Growth inhibition of human SR cells measured after 48 hrs by SRB assay
    Growth inhibition of human SR cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    SUP-B15 IC50
    0.111 μM
    Compound: imatinib
    Antiproliferative activity against human SUP-B15 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    Antiproliferative activity against human SUP-B15 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
    		[PMID: 16415863]
    SW-620 GI50
    23.44 μM
    Compound: Imatinib
    Growth inhibition of human SW-620 cells measured after 48 hrs by SRB assay
    Growth inhibition of human SW-620 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    T47D GI50
    19.91 μM
    Compound: Imatinib
    Growth inhibition of human T47D cells measured after 48 hrs by SRB assay
    Growth inhibition of human T47D cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    TK-10 GI50
    26.85 μM
    Compound: Imatinib
    Growth inhibition of human TK-10 cells measured after 48 hrs by SRB assay
    Growth inhibition of human TK-10 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    U-251 GI50
    17.99 μM
    Compound: Imatinib
    Growth inhibition of human U-251 cells measured after 48 hrs by SRB assay
    Growth inhibition of human U-251 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    U2OS IC50
    27.15 μM
    Compound: Imatinib
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35239349]
    U-87MG ATCC IC50
    3.8 x 10-5 M
    Compound: 1
    Cytotoxicity against human U87MG cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human U87MG cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    U-937 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity in human U937 cells after 72 hrs by CCK8 assay
    Antiproliferative activity in human U937 cells after 72 hrs by CCK8 assay
    		[PMID: 30317026]
    U-937 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human U937 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    Antiproliferative activity against human U937 cells measured after 72 hrs by CellTiter-Glo or CCK8 assay
    		[PMID: 27966954]
    U-937 GI50
    > 10 μM
    Compound: 1
    Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay
    		[PMID: 27077705]
    U-937 GI50
    > 10 μM
    Compound: Imatinib
    Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    U-937 IC50
    > 1000 nM
    Compound: Imatinib
    Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    U-937 IC50
    12.44 μM
    Compound: Imatinib
    Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 28029512]
    U-937 IC50
    16.59 μM
    Compound: Imatinib
    Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by CCK8 assay
    		[PMID: 36242991]
    UACC-257 GI50
    21.13 μM
    Compound: Imatinib
    Growth inhibition of human UACC-257 cells measured after 48 hrs by SRB assay
    Growth inhibition of human UACC-257 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    UACC-62 GI50
    19.01 μM
    Compound: Imatinib
    Growth inhibition of human UACC-62 cells measured after 48 hrs by SRB assay
    Growth inhibition of human UACC-62 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    UO-31 GI50
    22.34 μM
    Compound: Imatinib
    Growth inhibition of human UO-31 cells measured after 48 hrs by SRB assay
    Growth inhibition of human UO-31 cells measured after 48 hrs by SRB assay
    		[PMID: 32942186]
    WM 266-4 IC50
    3.7 x 10-5 M
    Compound: 1
    Cytotoxicity against human WM266.4 cells after 72 hrs by alamar-blue cell viability assay
    Cytotoxicity against human WM266.4 cells after 72 hrs by alamar-blue cell viability assay
    		[PMID: 19301902]
    In Vitro

    Imatinib (STI571) inhibits c-Kit autophosphorylation, activation of MAPK, and activation of Akt without altering total protein levels of c-kit, MAPK, or Akt. The concentration that produces 50% inhibition for these effects is approximately 100 nM[1].
    Imatinib (STI571) is very effective (in vitro IC50 of 25 nM) against the chronic myeloid leukemia-causing kinase Bcr-Abl. Imatinib also efficiently inhibits Kit (in vitro IC50, 410 nM) and PDGFR (in vitro IC50, 380 nM)[2].
    Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and inhibits Bcr/Abl, v-Abl, Tel/Abl, the native PDGFβ receptor, and c-Kit, but it does not inhibit Src family kinases, c-Fms, Flt3, the EGFR or multiple other tyrosine kinases. Imatinib inhibits tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC50 of approximately 0.5 μM in each case, but it has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2[4].
    The IC50s of Imatinib(STI571) is a multi-target inhibitor of v-Abl, c-Kit and on BON-1 and H727 cells after exposure for 48 h are 32.4 and 32.8 μM, respectively[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Imatinib Related Antibodies
    In Vivo

    In the phosphorothioate antisense oligodeoxynucleotides (PS-ASODN) group, tumor growth is inhibited by 59.437%, which is markedly higher than in the Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and group (11.071%) and liposome negative control group (2.759%). Telomerase activity is significantly lower (P<0.01) in the PS-ASODN group (0.689±0.158) compare with the Imatinib group (1.838±0.241), liposome negative control group (2.013±0.273), and saline group (2.004±0.163)[7].
    Imatinib (25 mg/kg/day, p.o.) suppresses the growth of endometriotic tissue and reduces the number of ovarian follicles in a rat model. Imatinib effectively treats experimental endometriosis by its inhibitor effects on angiogenesis and cell proliferation[8].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    493.60

    Formula

    C29H31N7O
    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    CN(CC1)CCN1CC2=CC=C(C(NC3=CC=C(C)C(NC4=NC(C5=CC=CN=C5)=CC=N4)=C3)=O)C=C2
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 12.5 mg/mL (25.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0259 mL 10.1297 mL 20.2593 mL
    5 mM 0.4052 mL 2.0259 mL 4.0519 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.25 mg/mL (2.53 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1.25 mg/mL (2.53 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: 11 mg/mL (22.29 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.95%

    SDS (392 KB)

    COA (265 KB) LCMS (265 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [4]

    BON-1 cells (7,500 per well) and NCI-H727 cells (5,000 per well) are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 h (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated. Experiments are done in triplicates[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [6][7]

    Mice[6]
    The 40 tumor-bearing SCID mice are randomly divided into four groups (10 mice per group): the PS-ASODN group (5 μM, each mouse receives 0.2 mL by intratumor injection once daily); Imatinib group (0.1 mg/g body weight); liposome negative control group (0.01 mL/g); and saline group (0.01 mL/g). The mice in each group receive the relevant treatment by intra-tumor injection once daily from day 7 to day 28 after implantation. After 28 d, the mice are sacrificed, and tumor weight and longest and shortest diameters are measured by electronic scale and vernier caliper, respectively. Inhibition of tumor growth is calculated.
    Rats[7]
    Adult female Wistar-Albino rats (220-240 g) are used. Twenty-one days after the first surgical procedure, the rats undergo a second laparotomy to evaluate the occurrence of endometriosis. Twenty-four rats have visually confirmed endometriotic implants and are randomized into three groups to receive Imatinib (25 mg/kg/day, p.o.), Anastrozole (0.004 mg/day, p.o.), or normal saline (0.1 mL, i.p.) for 14 days.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.0259 mL 10.1297 mL 20.2593 mL 50.6483 mL
    5 mM 0.4052 mL 2.0259 mL 4.0519 mL 10.1297 mL
    10 mM 0.2026 mL 1.0130 mL 2.0259 mL 5.0648 mL
    15 mM 0.1351 mL 0.6753 mL 1.3506 mL 3.3766 mL
    20 mM 0.1013 mL 0.5065 mL 1.0130 mL 2.5324 mL
    25 mM 0.0810 mL 0.4052 mL 0.8104 mL 2.0259 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Imatinib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Imatinib152459-95-5STI571 CGP-57148BSTI 571STI-571Bcr-AblPDGFRc-KitSARS-CoVAutophagyPlatelet-derived growth factor receptorSCFRCD117SARS coronavirusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Imatinib
    Cat. No.:
    HY-15463
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (392 KB) Français - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Español - ES (392 KB) Swedish - SV (392 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.